Delivery Order 36F79725D0093-36C26226F0313
Award Date 7/27/26
Potential Completion Date 7/26/27
Potential Value $180K
Federal Agency
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Bedford, MA 01730, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Veterans Integrated Service Network 20 issued a $469,133.60 delivery order to Progenics Pharmaceuticals Inc. on July 1, 2026, for PYLARIFY (piflufolastat F-18) injections, a radiopharmaceutical diagnostic imaging agent used in positron emission tomography scans for prostate cancer detection. This delivery order is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), the GSA-administered master contract vehicle for pharmaceutical procurement across federal agencies....
- Veterans Integrated Service Network 12 issued a $2,959,150.40 delivery order to Progenics Pharmaceuticals Inc. on May 1, 2026, for PYLARIFY (piflufolastat F-18) prostate imaging radiopharmaceuticals under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The order is firm fixed-price with no set-aside designation and extends through April 30, 2030. Place of performance is Bedford, MA. PYLARIFY is a radioactive diagnostic imaging agent used in positron emission tomography scans...
- Veterans Integrated Service Network 7 issued a delivery order to Progenics Pharmaceuticals Inc. on September 1, 2023, for PYLARIFY (piflufolastat F-18) radiopharmaceutical supply, with a ceiling value of $3,753,068.80 and an ultimate completion date of August 31, 2028. The order is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). Place of performance is New York, NY 10007. Progenics Pharmaceuticals, operating as a division of Lantheus Medical Imaging, Inc.,...
- Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a delivery order valued at $819,179.44 by Veterans Integrated Service Network 20 (VISN 20) on July 1, 2026, for the supply of PYLARIFY (piflufolastat F-18), a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans for prostate cancer detection and localization. This firm fixed-price delivery order, which carries no set-aside designation, has an ultimate completion...
- Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., has been awarded a firm fixed-price delivery order valued at $541,308 by Veterans Integrated Service Network 1 (VISN 1) for the supply of PYLARIFY (piflufolastat F-18), a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans for prostate cancer detection and localization. The award, issued on October 3, 2025, with an ultimate completion date of September 30, 2026, carries no...
- Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a $599,047.52 firm fixed-price delivery order by Veterans Integrated Service Network 5 on February 1, 2026, for PYLARIFY (piflufolastat F-18) injection radiopharmaceuticals. The contract, with an ultimate completion date of March 1, 2026, contains no set-aside designation and represents performance at the company's facility in Bedford, Massachusetts. This delivery order falls under the...
- Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging Inc., was awarded a delivery order valued at $4.7M by Veterans Integrated Service Network 22 (a civilian component of the Department of Veterans Affairs) on November 4, 2025, for the supply of PYLARIFY (piflufolastat F-18), a radioactive diagnostic imaging agent used in positron emission tomography scans for prostate cancer detection and localization. This delivery order, which is not set aside for any specific...
- Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging Inc., received a $1.06M delivery order from Veterans Integrated Service Network 10 on October 1, 2024, for PYLARIFY (F18 piflufolastat), a diagnostic radiopharmaceutical used in positron emission tomography scans to detect and image prostate cancer. This modification to the delivery order de-obligated excess funds and carries a firm fixed-price contract structure with a completion date of September 30, 2025. The contract...
- This delivery order for $1,024,876.48 from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 6 awards Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc., to provide PYLARIFY F 18 under the Pharmaceuticals and Drugs federal supply schedule. The order is for the delivery of the radioactive diagnostic agent Pylarify, also known as Piflufolastat F-18, used in positron emission...
- Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a delivery order valued at $332,280.71 by Veterans Integrated Service Network 20 (VISN 20) on July 5, 2022, for the supply of PYLARIFY (piflufolastat F-18), a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans for prostate cancer detection. This is a firm fixed-price contract with no set-aside designation and an ultimate completion date of July 4, 2023. The...